Alzheimer's research & therapy

Exosomes from human stem cells may reduce Alzheimer's damage by protecting brain cells and controlling immune response through a specific RNA

Updated

Abstract

Exosomes derived from human umbilical cord mesenchymal stem cells (hUC-MSCs) significantly improved spatial memory deficits in APP/PS1 mice.

  • Exosomes containing the long non-coding RNA lncRNA-9969 reduced cellular damage and enhanced amyloid-beta clearance in an Aβ-injured cell model.
  • Treatment with exosomes that delivered lncRNA-9969 led to increased levels of synaptic proteins and activation of autophagy pathways in the hippocampus of APP/PS1 mice.
  • The protective effects of exosomes were diminished when lncRNA-9969 was knocked down, indicating its role in neuroprotection.
  • lncRNA-0021, the mouse equivalent of lncRNA-9969, may regulate neuroinflammation and metabolic disturbances through its interaction with miR-6361.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Ethics approval and consent to participate: The experiments about hUC-MSCs conformed to the standards set by the Declaration of Helsinki; and the study methodologies were approved by the local ethics committee-stem cell clinical Research Institute, China-Japan Union Hospital, Jilin University. Institutional Ethics approval No. is 2018122502. Date of approval is 2018, Dec., 25th. The donor provided written informed consent to donate the umbilical cord for extraction of hUC-MSCs. The informed consent was signed on 2019, Sep., 17th. All animal experiments comply with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1996) and approval from the Institutional Animal Care and Use Committee of Jilin University. The work has been reported in line with the ARRIVE guidelines 2.0. Committee of Experimental Animal Welfare Ethics, College of Life Sciences, Jilin University. Title of the approved project is “The mechanistic study of lncRNA CLIC6 derived from human umbilical cord mesenchymal stem cell exosomes in mediating the miR-31-5p/RAB27A axis for the treatment of Alzheimer's disease”. Appl. No. is YNPZSY2025062, Date of approval is 2025, Aug., 14th. Consent for publication: Consent for publication is included in the written informed consent obtained from all participants. Competing interests: The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free